SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-289082
Filing Date
2020-11-09
Accepted
2020-11-09 16:16:10
Documents
14
Period of Report
2020-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d715890d8k.htm   iXBRL 8-K 25922
2 EX-99.1 d715890dex991.htm EX-99.1 49860
6 GRAPHIC g715890g1109234658375.jpg GRAPHIC 3726
  Complete submission text file 0001193125-20-289082.txt   208575

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ccxi-20201109.xsd EX-101.SCH 3082
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ccxi-20201109_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ccxi-20201109_pre.xml EX-101.PRE 10961
7 EXTRACTED XBRL INSTANCE DOCUMENT d715890d8k_htm.xml XML 3231
Mailing Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Business Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 650-210-2900
ChemoCentryx, Inc. (Filer) CIK: 0001340652 (see all company filings)

IRS No.: 943254365 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35420 | Film No.: 201297883
SIC: 2834 Pharmaceutical Preparations